Class / Patent application number | Description | Number of patent applications / Date published |
514618000 | Sulfur in R | 42 |
20080207761 | Pharmaceutical formulations of modafinil - Compositions of modafinil and methods of treating neurologically related conditions with the administration of modafinil. Also compositions that include modafinil and one or more excipients such as diluents, disintegrants, binders and lubricants. | 08-28-2008 |
20080221216 | Use of modafinil to treat spasticity - The invention provides a method of reducing spasticity in a mammal involving administering modafinil or related compounds. The spasticity can be secondary to multiple sclerosis, spinal cord injury, stroke, brain injury, and other causes. | 09-11-2008 |
20080312329 | Nonpeptide Inhibitors of Matrix Metalloproteinases - Disclosed are selective inhibitors of matrix metalloproteinases represented by the following formula (I). | 12-18-2008 |
20090018202 | Modafinil compositions - Polymorphs and solvates of racemic, enantiomerically pure, and enantiomerically mixed modafinil are formed and discussed. In addition, said forms are described as useful for the treatment of many conditions including, but not limited to, narcolepsy. | 01-15-2009 |
20090076158 | DEUTERIUM-ENRICHED BICALUTAMIDE - The present application describes deuterium-enriched bicalutamide, pharmaceutically acceptable salt forms thereof, and methods of treating using the same. | 03-19-2009 |
20090082461 | DEUTERIUM-ENRICHED MODAFINIL - The present application describes deuterium-enriched modafinil, pharmaceutically acceptable salt forms thereof, and methods of treating using the same. | 03-26-2009 |
20090082462 | DEUTERIUM-ENRICHED ARMODAFINIL - The present application describes deuterium-enriched amodafinil, pharmaceutically acceptable salt forms thereof, and methods of treating using the same. | 03-26-2009 |
20090099264 | Fluoroalkylamine Derivatives as Cathepsin Inhibtors - The present invention provides compounds of formula I which are inhibitors of cathepsin S and as such are useful in the prevention and treatment of cathepsin S dependent diseases and conditions including, but not limited to, chronic obstructive pulmonary disease (COPD) and pain. | 04-16-2009 |
20090105346 | Novel crystalline forms of armodafinil and preparation thereof - The invention encompasses crystalline forms of armodafinil, processes for preparing the crystalline forms of armodafinil, pharmaceutical formulation thereof, and method of treating excessive sleepiness using the formulations of the invention. | 04-23-2009 |
20090156683 | FAST RELEASE SOLID FORMULATION, PREPARATION AND USE THEREOF - The present invention relates to a chemically stable formulation of florfenicol, (and structurally related compounds) in compositions such as soluble blended powders, granules, fast-dissolving tablets or pellets suitable for rapid release of the drug in water, and to methods and kits for treating animals with aqueous compositions including florfenicol. | 06-18-2009 |
20090270510 | GLYCINE TRANSPORT INHIBITORS - The present invention relates to compounds of formula (I), or salts or solvates thereof, their use in the manufacture of medicaments for treating neurological and neuropsychiatric disorders, in particular psychoses, dementia or attention deficit disorder. The invention further comprises processes to make these compounds and pharmaceutical formulations thereof. | 10-29-2009 |
20090270511 | PRODRUGS OF INHIBITORS OF CATHEPSIN S - The present invention provides compounds of formula (I) which are prodrugs of inhibitors of cathepsin S and as such are useful in the prevention and treatment of cathepsin S dependent diseases and conditions including, but not limited to, chronic obstructive pulmonary disease (COPD) and pain. | 10-29-2009 |
20090270512 | Pan-Antagonists For The Androgen Receptor And Androgen Receptor Mutants Associated With Anti-Androgen Withdrawal - Disclosed herein are novel antagonists of the androgen receptor and androgen receptor mutations associated with clinical failure of currently prescribed anti-androgens and use of said antagonists in the treatment of conditions associated with inappropriate activation of the androgen receptor. | 10-29-2009 |
20090281192 | Process for the Preparation of and Crystalline Forms of Optical Enantiomers of Modafinil - The invention relates to a polymorphic form of (−)-modafinil that produces a powder X-ray diffraction spectrum comprising intensity peaks corresponding to interplanar spacings of about 12.38, 8.58, 7.34, 5.00 and 4.09 Å, and a process for the preparation thereof. | 11-12-2009 |
20090281193 | Process for the Preparation of and Crystalline Forms of Optical Enantiomers of Modafinil - The invention relates to a polymorphic form of (−)-modafinil that produces a powder X-ray diffraction spectrum comprising intensity peaks corresponding to interplanar spacings of about 9.45, 7.15, 5.13, 4.15 and 3.67 Å, and a process for the preparation thereof. | 11-12-2009 |
20090292025 | Novel crystalline forms of armodafinil and preparation thereof - The invention encompasses crystalline forms of armodafinil, processes for preparing the crystalline forms, and pharmaceutical formulation. | 11-26-2009 |
20090318559 | MODAFINIL-BASED TREATMENT FOR PREMATURE EJACULATION - Methods and compositions comprising modafinil are described for treating premature ejaculation in a male individual. | 12-24-2009 |
20090318560 | FORMULATIONS FOR CATHEPSIN K INHIBITORS - The instant invention relates to pharmaceutical compositions comprising cathepsin K inhibitors as the active ingredient with excipients which include binders, diluents, lubricants, and disintegrants. Also disclosed are processes for making said pharmaceutical compositions for oral and intravenous delivery. | 12-24-2009 |
20100010092 | USE OF MODAFINIL TO TREAT RESTLESS LEG SYNDROME - A method for relieving, treating, improving or attenuating one or more symptoms of RLS and related movement disorders such as PLMS, and snoring ICSD 780.53-1 is disclosed. The method includes the administration to a host afflicted with RLS or related disorder a pharmaceutically effective amount of a modafinil compound or a related compound. The method of the present invention is to treat a host to reduce or diminish snoring, the unpleasant leg sensations associated with unwanted leg movements and to diminish or eliminate the unwanted, involuntary leg movements at rest, awake or asleep, typically occurring in the evenings and at night. | 01-14-2010 |
20100010093 | ANTIPARASITIC AGENTS - The present invention relates to compounds of the formula (I) | 01-14-2010 |
20100022653 | Process for the Preparation of and Crystalline Forms of Optical Enantiomers of Modafinil - The invention relates to a polymorphic form of (−)-modafinil that produces a powder X-ray diffraction spectrum comprising intensity peaks corresponding to interplanar spacings of about 8.54, 4.56, and 3.78 Å, and a process for the preparation thereof. | 01-28-2010 |
20100048717 | CATHEPSIN B INHIBITORS - Compounds of formula (I): are found to be selective inhibitors of cathepsin B, and hence useful in treating a variety of pathological conditions. | 02-25-2010 |
20100048718 | Process for the Preparation of and Crystalline Forms of Optical Enantiomers of Modafinil - The invention relates to a polymorphic form of (−)-modafinil that produces a powder X-ray diffraction spectrum comprising intensity peaks corresponding to interplanar spacings of about 5.23, 5.03, 4.22 and 4.10 Å, and a process for the preparation thereof. | 02-25-2010 |
20100048719 | Process for the Preparation of and Crystalline Forms of Optical Enantiomers of Modafinil - The invention relates to a polymorphic form of (−)-modafinil that produces a powder X-ray diffraction spectrum comprising intensity peaks corresponding to interplanar spacings of about 12.31, 8.54, 7.27 and 3.62 Å, and a process for the preparation thereof. | 02-25-2010 |
20100048720 | Process for the Preparation of and Crystalline Forms of Optical Enantiomers of Modafinil - The invention relates to a polymorphic form of (−)-modafinil that produces a powder X-ray diffraction spectrum comprising intensity peaks corresponding to interplanar spacings of about 14.14, 10.66, 7.80 and 4.02 Å, and a process for the preparation thereof. | 02-25-2010 |
20100197794 | FLUORINE-CONTAINING ORGANOSULFUR COMPOUND AND PESTICIDAL COMPOSITION COMPRISING THE SAME - There is provided a fluorine-containing organosulfur compound having an excellent controlling effect on arthropod pests represented by the formula (I): wherein G represents an oxygen atom or a sulfur atom; R | 08-05-2010 |
20100204334 | Intranasal Delivery of Modafinil - Modafinil is selectively delivered to the brain, minimizing delivery to the blood, of a person in need thereof by administering to the person a therapeutically-effective dosage of modafinil, wherein the dosage is less than 1 mg, formulated in a lipid microemulsion (LME) and selectively delivered to the upper third of the nasal cavity. The method may be implemented with an intranasal pharmaceutical delivery device loaded with a modafinil composition and adapted to deliver the dosage to the upper third of the nasal cavity. | 08-12-2010 |
20100210731 | Modafinil Compositions - Polymorphs and solvates of racemic, enantiomerically pure, and enantiomerically mixed modafinil are formed and discussed. In addition, said forms are described as useful for the treatment of many conditions including, but not limited to, narcolepsy. | 08-19-2010 |
20100234468 | NOVEL PROCESS - The present invention relates to a process for the preparation of polymorphic forms of the R- and S-enantiomers of modafinil, R-(−)-2-benzhydrylsulfinylacetamide and S-(+)-2-benzhydrylsulfinylacetamide respectively. | 09-16-2010 |
20100267835 | Methods of treating disorders of trigeminalvascular activation - Alpha-aminoamide derivatives useful in the treatment of disorders of trigeminalvascular activation are disclosed. | 10-21-2010 |
20100324146 | Dendrimeric Enzyme Inhibitors - The present invention relates generally to the use of dendrimer compounds bearing anionic surface groups as inhibitors of hyaluronidase and their use in the treatment of diseases and conditions in which excessive, abnormal or unwanted levels of hyaluronidase are involved or implicated, or in the treatment of diseases or conditions in which the presence or administration of hyaluronic acid is therapeutically effective. The present invention also relates to pharmaceutical compositions and methods for the treatment of such diseases and conditions. | 12-23-2010 |
20100331418 | Pan-Antagonists For The Androgen Receptor And Androgen Receptor Mutants Associated With Anti-Androgen Withdrawal - Disclosed herein are novel antagonists of the androgen receptor and androgen receptor mutations associated with clinical failure of currently prescribed anti-androgens and use of said antagonists in the treatment of conditions associated with inappropriate activation of the androgen receptor. | 12-30-2010 |
20110230563 | AMIDOACETONITRILE COMPOUNDS AND PESTICIDAL COMPOSITION THEREOF - Novel amidoacetonitrile compounds are disclosed. The compounds have pesticidal properties and are suitable for controlling endoparasites on warm-blooded animals. | 09-22-2011 |
20110306669 | RAPID ONSET AND SHORT TERM MODAFINIL COMPOSITIONS AND METHODS OF USE THEREOF - Compositions are described that comprise a modafÊnil component that is a combination of the d- and l-enantiomers of modafinil and wherein the modafÊnil component is greater than 50% by weight d-modafÊnil for use in promoting or enhancing the state of wakefulness, alertness, and/or central nervous system stimulation in an individual. | 12-15-2011 |
20110306670 | PENTAFLUOROSULFANYLBENZOYLGUANIDINES, PROCESSES FOR THEIR PREPARATION, THEIR USE AS MEDICAMENTS OR DIAGNOSTIC AIDS, AND MEDICAMENTS COMPRISING THEM - Pentafluorosulfanylbenzoylguanidines of the formula I and II | 12-15-2011 |
20120316244 | Pharmaceutical Formulations of Modafinil - Compositions of modafinil and methods of treating neurologically related conditions with the administration of modafinil. Also compositions that include modafinil and one or more excipients such as diluents, disintegrants, binders and lubricants. | 12-13-2012 |
20120322880 | Pharmaceutical Formulations of Modafinil - Compositions of modafinil and methods of treating neurologically related conditions with the administration of modafinil. Also compositions that include modafinil and one or more excipients such as diluents, disintegrants, binders and lubricants. | 12-20-2012 |
20130324610 | CATHEPSIN CYSTEINE PROTEASE INHIBITORS - This invention relates to deuterated compounds which are useful for treating diseases in which inhibition of bone resorption is indicated, such as osteoporosis. | 12-05-2013 |
20150051290 | KINASE INHIBITORS FOR THE TREATMENT OF CANCER - The present invention relates to kinase inhibitors for the treatment of cancer. Specifically, the present invention relates to the use of aminoactonitrile derivatives (AADs) in the treatment of cancer. | 02-19-2015 |
20150073055 | USE OF MODAFINIL IN THE TREATMENT OF COCAINE ADDICTS - The present invention relates to the application of modafinil in cocaine addiction. The modafinil used is its dextro-rotatory enantiomer (S modafinil), having a release time of less than 1 hour and wakening effect of less than 4 hours. It is absorbed orally as a pharmaceutical composition, each unit dose including from 25 to 200 mg of S modafinil. The pharmaceutical composition can be used as a substitute treatment for cocaine addicts. | 03-12-2015 |
20150105470 | PROCESS FOR OBTAINING A MODAFINIL-BASED PHARMACEUTICAL COMPOSITION, RESULTING PHARMACEUTICAL COMPOSITION AND USE THEREOF - The present invention relates to a novel method for obtaining a pharmaceutical composition based on modafinil. This method consists of solubilizing S modafinil in a fluid in the supercritical state and then after expansion of said fluid, recovering S modafinil by causing it to be absorbed at the surface by a support appearing as granules. Said fluid may be CO | 04-16-2015 |
20160106679 | TABLET WITH INCREASED DRUG LOAD OF ODANACATIB - The present invention relates to pharmaceutical tablets comprising amorphous compound I in the form of its free base or pharmaceutically acceptable salts of compound I. | 04-21-2016 |